{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-035337","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.006896+00:00","generated_at":"2026-05-17T06:14:09.412394+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Grace Therapeutics receives sixth U.S. patent for GTx-104 dosing regimen; protection extended to 2043","bullets":["US Patent 12,414,943 issued for I.V. nimodipine dosing regimen used in Phase 3 STRIVE-ON trial.","First method-of-use patent for GTx-104; adds to five composition patents expiring 2037.","Patent protection for GTx-104 extended to 2043.","GTx-104 is a clinical-stage injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).","Orphan Drug Designation provides 7 years of marketing exclusivity upon FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-035337","json":"https://secwatch.observer/filing/0001140361-25-035337.json","markdown":"https://secwatch.observer/filing/0001140361-25-035337.md","text":"https://secwatch.observer/filing/0001140361-25-035337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125035337/0001140361-25-035337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125035337/ef20055717_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:14:09.412394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}